You are here

Gene Based Therapy for Congestive Heart Failure P2 SBIR

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44HL108581-02A1
Agency Tracking Number: R44HL108581
Amount: $2,623,563.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
870 MARTIN LUTHER KING JR BLVD
CHAPEL HILL, NC 27514-2600
United States
DUNS: 6064300
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DANIEL SIGG
 (651) 200-3485
 dcsigg@gmail.com
Business Contact
 DANIEL SIGG
Phone: (651) 200-3485
Email: dcsigg@gmail.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Congestive heart failure is a major cause of morbidity and mortality in the United States. While progress in conventional treatments is making steady and incremental gains to reduce heart failure mortality, there is a critical need to explore new therapeutic approaches. It is now apparent that gene therapy has broader potential in diseases such as congestive heart failure. Improvement in our understanding of the molecular mechanisms of heart failure, along with the development of novel and safer vectors for gene delivery, have led to the identification of novel targets that are difficult to manipulate pharmacologically but may be more amenable to gene therapy. In the last few years calcium cycling abnormalities and specifically deficiencies in sarcoplasmic reticulum calcium uptake have been hallmarks of advanced heart failure. The complex of SERCA2a-phospholamban-Protein phosphatase 1 has been difficult to target pharmacologically. However the encouraging results from

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government